A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jamie Chaft, MD
Memorial Sloan Kettering, USA
Principal Investigator - Masahiro Tsuboi, MD
National Cancer Center Hospital East, Japan
Principal Investigator - Walter Weder, MD
Thoraxchirurgie Bethanien, Switzerland
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
158 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Graz, Austria
- Research Site
Vienna, Austria
- Research Site
Barretos, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Jaú, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Recife, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
Santa Maria, Brazil
- Research Site
São José do Rio Preto, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Panagyurishte, Bulgaria
- Research Site
Pleven, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Las Condes, Chile
- Research Site
Santiago, Chile
- Research Site
Santiago, Chile
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Changsha, China
- Research Site
Changsha, China
- Research Site
Chengdu, China
- Research Site
Chongqing, China
- Research Site
Guangzhou, China
- Research Site
Guangzhou, China
- Research Site
Guangzhou, China
- Research Site
Guangzhou, China
- Research Site
Hangzhou, China
- Research Site
Hangzhou, China
- Research Site
Kunming, China
- Research Site
Nanchang, China
- Research Site
Nantong, China
- Research Site
Shandong, China
- Research Site
Shanghai, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Dec 2020
- Primary completion
- 15 Oct 2024
- Completion
- 13 Jun 2029
- Last update posted
- 5 Jun 2026
- Registered enrollment
- 358
- Registry id
- NCT04351555
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.